Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has recommended approval of Camzyos for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, or HCM, in adult patients. The European Commission, which has the authority to approve medicines for the European Union, will now review the CHMP opinion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY: